Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children

HU Wei-Wei; NURIDING Hailiqiguli; YAN Mei

PDF(876 KB)

Chinese Journal of Contemporary Pediatrics ›› 2012, Vol. 14 ›› Issue (11) : 852-855.

CLINICAL RESEARCH

Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children

HU Wei-Wei, NURIDING Hailiqiguli, YAN Mei

Author information +

History +

Abstract

OBJECTIVE: To study blood concentrations of methotrexate (MTX) in Uyghur and Han children with acute lymphoblastic leukemia (ALL), and to provide criteria for judging the incidence of adverse effects of MTX. METHODS: Twenty-eight children with ALL (15 Han children and 13 Uyghur children), who received high-dose MTX chemotherapy, were divided into >10 μmol/L and ≤10 μmol/L groups according to 24-hour blood concentration of MTX, and divided into >1.0 μmol/L and ≤1.0 μmol/L groups according to 48-hour blood concentration of MTX. Enzyme multiplied immunoassay was used to measure blood concentrations of MTX in the MTX-treated children at 24 and 48 hours after MTX administration, and the adverse effects were observed. RESULTS: There was no significant difference in the incidence of adverse effects between the >10 μmol/L and ≤10 μmol/L groups (P>0.05). The >1.0 μmol/L group showed higher incidences of gastrointestinal reactions and mucosal injuries than the ≤1.0 μmol/L group (P0.05). Compared with Uyghur children, Han children showed higher 24- and 48-hour blood concentrations of MTX (P<0.05) and higher incidence of abnormal liver function, mucosal injuries, and bone marrow suppression (P<0.05). CONCLUSIONS: The 24-hour blood concentration of MTX cannot be used to predict the incidence of adverse effects in MTX chemotherapy, but 48-hour blood concentration of MTX is helpful in this regard. There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy. Monitoring of blood MTX concentration maybe significant for timely adjustment of MTX dosage and individualized MTX chemotherapy.

Key words

Acute lymphoblastic leukemia / Methotrexate / Adverse effect / Monitoring of blood MTX concentration / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HU Wei-Wei, NURIDING Hailiqiguli, YAN Mei. Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children[J]. Chinese Journal of Contemporary Pediatrics. 2012, 14(11): 852-855

References

［1］叶辉,顾龙君,陈静.儿童急性淋巴细胞白血病大剂量甲氨蝶呤治疗研究［J］.中华血液学杂志,2001,22 (7):385-386.

［2］韦润红,赵国兴,陈疏敏，程志.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病耐受性临床研究［J］. 儿科药学杂志,2006,12(3):12-14.

［3］唐薇,张瑛,杨龙,张峻.66 例小儿急淋白血病大剂量甲氨蝶呤化疗血药浓度监测及个体化给药［J］. 中国现代应用药学,2006,23(6):508-510.

［4］顾龙君.儿童急性淋巴细胞白血病诊疗建议（第三次修订草案）［J］.中华儿科杂志,2006,44(5):392-395.

［5］陆爱东,张乐平,刘桂兰.大剂量甲氨蝶呤治疗急性淋巴细胞白血病的血药浓度研究［J］.实用儿科临床杂志,2004,19(1):36-38.

［6］Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, et al. Very highdosem ethotrexate ( 33.6 g /m2 ) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144 P［J］. Leuk Lymphoma, 2006, 47 (12): 2488-2504.

［7］詹其林,丁美琪,潘民,虞国慧，吴福红，邱晓星.大剂量甲氨蝶呤治疗急性淋巴细胞白血病和淋巴瘤副作用观察［J］.内科急危重症杂志,2008,14(4):207-209.

［8］刘莜梅,徐酉华,戴碧涛，宪莹，苏庸春. 大剂量甲氨蝶呤治疗儿童白血病毒副作用临床研究［J］.儿科药学杂志,2003,9 (5):45.

［9］徐卫群,汤永民,方澄清，宋华，石淑文，杨世隆，等. 大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病排泄延迟分析［J］. 中华血液学杂志,2005, 26(1):15-18.

［10］王玉成, 顾龙君. 甲氨蝶呤多聚谷氨酸盐在甲氨蝶呤治疗急性白血病中的作用及耐药机制研究进展［J］. 中国当代儿科杂志, 2000,2(5): 361-363.

［11］Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, et al. Methyleneterahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma［J］. Leuk Lymphoma, 2009, 50(6): 912-917.

［12］刘晶霞,陈洁平,谭文.亚甲基四氢叶酸还原酶基因多态性与急性淋巴细胞白血病患者甲氨喋呤化疗毒副反应的研究［J］.中国实验血液学杂志,2008,16(3):488-492.

［13］余慧,金润铭,白燕.急性淋巴细胞白血病患儿亚甲基四氢叶酸还原酶多态性与氨甲蝶呤毒副反应的研究［J］.中华儿科杂志,2005,43(4)：302.

［14］Treri-o LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects［J］. J Clin Oncol, 2009, 27(35): 5972-5978.

［15］张耀东,谭利娜,胡群,卫海燕,张小玲,熊昊.儿童急性淋巴细胞白血病免疫分型特征及其临床意义［J］.中国当代儿科杂志,2012, 14 (3): 188-191.